Increased circulating levels of FGF23: An adaptive response in primary hyperparathyroidism?

European Journal of Endocrinology

Volumn 166, Issue 1, 2012, Pages 55-60

  Witteveen, Janneke E ^a   Van Lierop, Antoon H ^a   Papapoulos, Socrates E ^a   Hamdy, Neveen A T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE; BETA LACTAMASE; BETA LACTAMASE CTX; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; VITAMIN D;

ADAPTIVE IMMUNITY; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL;

ADULT; CHOLECALCIFEROL; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROIDECTOMY;

EID: 84055193412     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0523     Document Type: Article

References (41)

1. 3. Biochemical Journal 1999 343 705-712. (doi:10.1042/0264-6021:3430705)
2. Kurnik BR & Hruska KA. Mechanism of stimulation of renal phosphate transport by 1,25-dihydroxycholecalciferol. Biochimica et Biophysica Acta 1985 817 42-50. (doi:10.1016/0005-2736(85)90066-5)
3. +/phosphate co-transporter. Biochemical Journal 1997 324 927-934.
4. Kurnik BR & Hruska KA. Effects of 1,25-dihydroxycholecalciferol on phosphate transport in vitamin D-deprived rats. American Journal of Physiology 1984 247 F177-F184. (Pubitemid 14091542)
5. Liang CT, Barnes J, Balakir R, Cheng L & Sacktor B. In vitro stimulation of phosphate uptake in isolated chick renal cells by 1,25-dihydroxycholecalciferol. PNAS 1982 79 3532-3536. (doi:10.1073/pnas.79.11. 3532)
6. 3 administered in vivo on phosphate uptake by isolated chick renal cells. American Journal of Physiology 1982 242 C312-C318.
7. Virkki LV, Biber J, Murer H & Forster IC. Phosphate transporters: a tale of two solute carrier families. American Journal of Physiology. Renal Physiology 2007 293 F643-F654. (doi:10.1152/ajprenal.00228.2007)
8. 3. Identification of a vitamin D-responsive element in the human NAPi-3 gene. Journal of Biological Chemistry 1998 273 14575-14581. (doi:10.1074/jbc.273.23.14575)
9. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. Journal of Clinical Investigation 2008 118 3820-3828. (doi:10.1172/JCI36479)
10. Liu S, Gupta A & Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Current Opinion in Nephrology and Hypertension 2007 16 329-335. (doi:10.1097/MNH.0b013e3281ca6ffd)
11. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M & Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Structure and Function 2004 29 91-99. (doi:10.1247/csf.29.91)
12. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S & Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research 2004 19 429-435. (doi:10.1359/JBMR.0301264)
13. Burnett-Bowie SM, Henao MP, Dere ME, Lee H & Leder BZ. Effects of hPTH (1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. Journal of Bone and Mineral Research 2009 24 1681-1685. (doi:10.1359/jbmr.090406)
14. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M & Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Journal of the American Society of Nephrology 2006 17 1305-1315. (doi:10.1681/ASN.2005111185)
15. 3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. American Journal of Physiology. Gastrointestinal and Liver Physiology 2005 289 G1036-G1042. (doi:10.1152/ajpgi.00243.2005)
16. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H & Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. Journal of Bone and Mineral Research 2006 21 1187-1196. (doi:10.1359/jbmr.060507)
17. Ferrari SL, Bonjour JP & Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. Journal of Clinical Endocrinology and Metabolism 2005 90 1519-1524. (doi:10.1210/jc.2004-1039)
18. Larsson T, Nisbeth U, Ljunggren O, Juppner H & Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney International 2003 64 2272-2279. (doi:10.1046/j.1523-1755.2003.00328.x)
19. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T & Fujita T. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. Journal of Bone and Mineral Research 2007 25 419-422. (doi:10.1007/s00774-007-0779-3)
20. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H & Takeda E. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney International 2006 70 2141-2147. (Pubitemid 44871378)
21. Berndt T & Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology 2009 24 17-25. (doi:10.1152/physiol.00034.2008)
22. Khoshniat S, Bourgine A, Julien M, Weiss P, Guicheux J & Beck L. The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals. Cellular and Molecular Life Sciences 2010 68 205-218. (doi:10.1007/s00018-010-0527-z)
23. Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ & Kumar R. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. PNAS 2007 104 11085-11090. (doi:10.1073/pnas. 0704446104)
24. Markovich D, Verri T, Sorribas V, Forgo J, Biber J & Murer H. Regulation of opossum kidney (OK) cell Na/Pi cotransport by Pi deprivation involves mRNA stability. Pflügers Archiv 1995 430 459-463. (doi:10.1007/BF00373881)
25. Segawa H, Kaneko I, Yamanaka S, Ito M, Kuwahata M, Inoue Y, Kato S & Miyamoto K. Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. American Journal of Physiology. Renal Physiology 2004 287 F39-F47. (doi:10.1152/ajprenal.00375.2003)
26. Galitzer H, Ben-Dov I, Lavi-Moshayoff V, Naveh-Many T & Silver J. Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Current Opinion in Nephrology and Hypertension 2008 17 363-367. (doi:10.1097/MNH.0b013e328303e172)
27. Rhee Y, Farrow E, Lee R, Bivi N, Lazcano V, Plotkin L, White K & Bellido T. FGF23 expression is upregulated by PTH receptor activation in osteocytes in vitro and in vivo: a parathyroid-bone link influencing the endocrine function of osteocytes. Journal of Bone and Mineral Research 2009 24. S1 A1039. (doi:10.1002/jbmr.5650241301)
28. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J & Naveh-Many T. PTH increases FGF23 gene expression and mediates the high- FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. American Journal of Physiology. Renal Physiology 2010 299 F882-F889. (doi:10.1152/ajprenal.00360. 2010)
29. Bergwitz C & Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annual Review of Medicine 2010 61 91-104. (doi:10.1146/annurev.med.051308.111339)
30. Sridharan M, Cheung J, Moore AE, Frost ML, Fraser WD, Fogelman I & Hampson G. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcified Tissue International 2010 87 398-405. (doi:10.1007/s00223-010-9414-8)
31. Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama JJ, Shimada T, Yamazaki Y, Fukumoto S, Fukagaw M & Noguchi S. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. European Journal of Endocrinology 2004 151 55-60. (doi:10.1530/eje.0.1510055)
32. Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, Tahara H, Goto H, Miki T, Ishimura E, Sugimoto T, Ishikawa T, Inaba M & Nishizawa Y. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. European Journal of Endocrinology 2006 154 93-99. (doi:10.1530/eje.1.02053)
33. Tebben PJ, Singh RJ, Clarke BL & Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clinic Proceedings 2004 79 1508-1513. (doi:10.4065/79.12.1508)
34. Heijboer AC, Levitus M, Vervloet MG, Lips P, ter Wee PM, Dijstelbloem HM & Blankenstein MA. Determination of fibroblast growth factor 23. Annals of Clinical Biochemistry 2009 46 338-340. (doi:10.1258/acb.2009.009066)
35. Lopez I, Rodriguez-Ortiz E, Almaden Y, Guerrero F, Montes de Oca A, Pineda C, Shalhoub V, Rodriguez M & Aguilera-Tejero E. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney International 2011 80 475-482. (doi:10.1038/ki.2011.107)
36. Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M, Hsieh JC, Kaczmarska M, Haussler CA & Haussler MR. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. Journal of Bone and Mineral Research 2007 22 (Suppl 2) V2-V10. (doi:10.1359/jbmr.07s216)
37. Hruska KA, Mathew S, Lund R, Qiu P & Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney International 2008 74 148-157. (doi:10.1038/ki.2008.130)
38. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X & Quarles LD. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. Journal of the American Society of Nephrology 2007 18 2116-2124. (doi:10.1681/ASN.2006121385)
39. Block GA, Hulbert-Shearon TE, Levin NW & Port FK. Association of serum phosphorus and calcium!phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Diseases 1998 31 607-617. (doi:10.1053/ajkd.1998.v31.pm9531176)
40. Tonelli M, Sacks F, Pfeffer M, Gao Z & Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005 112 2627-2633. (doi:10.1161/CIRCULATIONAHA.105.553198)
41. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS & Collins MT. Determination of the elimination half-life of fibroblast growth factor-23. Journal of Clinical Endocrinology and Metabolism 2007 92 2374-2377. (doi:10.1210/jc.2006-2865)